NICE
UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma
In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.
NICE Not Backing AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Low Breast Cancer
Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.
UK's NICE Recommends Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer
The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.
NICE Declines to Recommend Menarini's Orserdu in ESR1-Mutant Breast Cancer in England
In a draft guidance, the institute did not recommend Orserdu, but is collecting additional data and public comments on this preliminary decision.
NICE Doesn't Recommend Biogen, Eisai's Alzheimer's Drug in Draft Guidance Despite MHRA Nod
After considering the data on Leqembi, the agency found that the four-to-six month slowing of disease progression wasn't enough benefit to justify its costs.